title: IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.
abstract: The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3-6, 2012 in San Diego, CA. The meeting drew over 800 participants who attended sessions on a wide variety of topics relevant to antibody research and development. As a prelude to the main events, a pre-conference workshop held on December 2, 2012 focused on intellectual property issues that impact antibody engineering. The Antibody Engineering Conference was composed of six sessions held December 3-5, 2012: (1) From Receptor Biology to Therapy; (2) Antibodies in a Complex Environment; (3) Antibody Targeted CNS Therapy: Beyond the Blood Brain Barrier; (4) Deep Sequencing in B Cell Biology and Antibody Libraries; (5) Systems Medicine in the Development of Antibody Therapies/Systematic Validation of Novel Antibody Targets; and (6) Antibody Activity and Animal Models. The Antibody Therapeutics conference comprised four sessions held December 4-5, 2012: (1) Clinical and Preclinical Updates of Antibody-Drug Conjugates; (2) Multifunctional Antibodies and Antibody Combinations: Clinical Focus; (3) Development Status of Immunomodulatory Therapeutic Antibodies; and (4) Modulating the Half-Life of Antibody Therapeutics. The Antibody Society's special session on applications for recording and sharing data based on GIATE was held on December 5, 2012, and the conferences concluded with two combined sessions on December 5-6, 2012: (1) Development Status of Early Stage Therapeutic Antibodies; and (2) Immunomodulatory Antibodies for Cancer Therapy.
authors.affiliation: MRC Prion Unit, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK.
authors.forename: Peter-Christian
authors.initials: PC
authors.lastname: Klöhn
authors.forename: Ulrich
authors.initials: U
authors.lastname: Wuellner
authors.forename: Nora
authors.initials: N
authors.lastname: Zizlsperger
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhou
authors.forename: Daniel
authors.initials: D
authors.lastname: Tavares
authors.forename: Sven
authors.initials: S
authors.lastname: Berger
authors.forename: Kirstin A
authors.initials: KA
authors.lastname: Zettlitz
authors.forename: Gabriele
authors.initials: G
authors.lastname: Proetzel
authors.forename: May
authors.initials: M
authors.lastname: Yong
authors.forename: Richard H J
authors.initials: RH
authors.lastname: Begent
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D002460:Cell Line; D006207:Half-Life; D006801:Humans; D018796:Immunoconjugates; D056747:Immunomodulation; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering / Q000379:methods*
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates
keywords: antibody engineering; antibody therapeutics; antibody-drug conjugates; bispecific antibodies; computational design